Beta-Blockers in Women May Increase Heart Failure Risk
In a recent article in Hypertension, researchers explored whether the effect of beta-blockers differed according to gender in patients with hypertension and no prior history of cardiovascular disease. The data were obtained from 954 women and 1,636 men with hypertension who were previously treated with beta-blockers, and the primary outcome was the prevalence of heart failure. Analyses were conducted to estimate the correlation between heart failure and all-cause mortality at 30 days. Read more.

Increased CVD Risk Associated With Severe Menopausal Symptoms
In a recent publication, researchers examined the correlations between different aspects of menopausal vasomotor symptoms and the risk of cardiovascular disease (CVD). According to the study, which pooled results from 23,365 women in six prospective studies, among women with menopausal vasomotor symptoms, the severity instead of the incidence of hot flushes and night sweats is linked to a greater risk of CVD. Read more.

FDA Bestows Breakthrough Therapy Moniker on Mavacamten
On July 23, 2020, the manufacturer of mavacamten announced that the FDA granted Breakthrough Therapy Designation to mavacamten, a novel oral allosteric modulator of cardiac myosin for treating symptomatic obstructive hypertrophic cardiomyopathy (HCM). In May 2020, the manufacturer announced positive results from the pivotal phase III EXPLORER clinical trial of mavacamten for the treatment of symptomatic patients with obstructive HCM. Read more.